Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

26 of 32 arms with a reported figure. Choose arms to narrow the chart.

months 21

Imatinib 400 mg. median progression-free survival: 18.9 months, median follow up 37.5 months

Imatinib 800 mg. median progression-free survival: 23.2 months, median follow up 37.5 months

Regorafenib 160 mg. median progression-free survival: 4.8 months, primary analysis

Regorafenib placebo. median progression-free survival: 0.9 months, primary analysis

Ripretinib 150 mg. median progression-free survival (BICR): 6.3 months, primary analysis

Ripretinib placebo. median progression-free survival (BICR): 1 months, primary analysis

Ripretinib 150 mg. median progression-free survival (IRR), ITT: 8 months, primary analysis

Ripretinib 150 mg. median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis

Ripretinib 150 mg. median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P

Ripretinib 50 mg. median progression-free survival (IRR), ITT: 8.3 months, primary analysis

Ripretinib 50 mg. median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis

Ripretinib 50 mg. median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory

Ripretinib 50 mg. median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory

Avapritinib 300 mg. median progression-free survival: 4.2 months, primary analysis

Avapritinib 160 mg. median progression-free survival: 5.6 months, primary analysis

Bezuclastinib + Sunitinib 600 mg + 37.5 mg. median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025

Bezuclastinib + Sunitinib 37.5 mg. median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025

Velzatinib (IDRX-42, GSK6042981) 300 mg. median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025

Olverembatinib (HQP1351) 30 to 50 mg. median progression-free survival: 25.7 months, cutoff 11.13.2025

NB003 not stated in source. median progression-free survival: 9.2 months, data as of March 2025

NB003 not stated in source. median progression-free survival: 13.7 months, data as of March 2025

Bars in this group share the unit months. 25.7 months is the longest reported value here. A different unit is not redrawn onto this scale.

weeks 4

Sunitinib 50 mg. median time to tumor progression: 27.3 weeks, interim analysis

Sunitinib 50 mg. median progression-free survival: 24.1 weeks, interim analysis

Sunitinib placebo. median time to tumor progression: 6.4 weeks, interim analysis

Sunitinib placebo. median progression-free survival: 6 weeks, interim analysis

Bars in this group share the unit weeks. 27.3 weeks is the longest reported value here. A different unit is not redrawn onto this scale.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.